Crizotinib for refractory vulvar malignant melanoma with equivocal MET amplification: a case report

Report the effect of crizotinib on one woman with refractory vulvar malignant melanoma and equivocal MET amplification.

One 62-year-old woman was diagnosed with vulvar malignant melanoma, AJCC stage IV, pT2aN0M1c. She received postoperative adjuvant therapy with 6 cycles of 75 mg/m² of cisplatin and 200 mg/m² of temozolomide, and then received pembrolizumab, nivolumab and brachytherapy for recurrence. However, she suffered multiple liver metastases and the recurrence was refractory to repeat pembrolizumab treatment. Next-generation sequencing examination revealed equivocal MET amplification. She received crizotinib (250 mg twice a day) based on the finding of equivocal MET amplification. Partial response was achieved based on the decreased size of liver metastases. However, liver metastasis deteriorated after 6 months of crizotinib. She died later despite salvage radiotherapy.

Next-generation sequencing may be suggested for refractory malignant melanoma. Crizotinib may be used to treat malignant melanoma with MET amplification.